Effects of A Long-Term Use of Carbocysteine on Frequency and Duration of Exacerbations in Patients with Bronchiectasis

Jordan Minov; Sasho Stoleski; Tatjana Petrova; Kristin Vasilevska; Dragan Mijakoski; Jovanka Karadzinska-Bislimovska

doi:10.3889/oamjms.2019.697

Authors

Jordan Minov Institute for Occupational Health of Republic of Macedonia, Skopje, Republic of Macedonia
Sasho Stoleski Institute for Occupational Health of Republic of Macedonia, Skopje, Republic of Macedonia
Tatjana Petrova Department of Pharmacy Practice, Chicago State University, Chicago, USA
Kristin Vasilevska Institute for Epidemiology and Biostatistics, Skopje, Republic of Macedonia
Dragan Mijakoski Institute for Occupational Health of Republic of Macedonia, Skopje, Republic of Macedonia
Jovanka Karadzinska-Bislimovska Institute for Occupational Health of Republic of Macedonia, Skopje, Republic of Macedonia

DOI:

https://doi.org/10.3889/oamjms.2019.697

Keywords:

Bronchiectasis, Carbocysteine, Daily diary card, Exacerbation, Long-term use

Abstract

BACKGROUND: The failure of mucus clearance in bronchiectasis can be improved by chest physiotherapy or/and mucoactive agents.

AIM: To assess the effects of long-term use of carbocysteine on frequency and duration of exacerbations in patients with bronchiectasis.

METHODS: We performed an observational, non-randomized, open study (a real-life study) including 64 patients with bronchiectasis divided into two groups, examined group (EG) and control group (CG). All participants were treated with appropriate treatment for the stable disease, but in the study, subjects of EG two capsules 375 mg carbocysteine three times a day was added over three months. Daily diary cards realised collection of data regarding the occurrence and duration of exacerbation in all study subjects.

RESULTS: Over the study period 43 exacerbations were documented, 17 in the EG and 26 in the CG, 10 (23.4%) of which required hospital treatment (four in the EG [23.5%] and six in the CG [23.1%]). A mean number of exacerbations over the study period was significantly lower in the EG (0.5 Â± 0.1) as compared to their mean number in the CG (0.8 Â± 0.2) (P = 0.0000). Mean duration of exacerbations expressed in days needed for complete resolution of symptoms or return of the symptoms to their baseline severity in the EG was significantly shorter than the mean duration of exacerbations in the CG (10.1 Â± 2.6 vs 12.8 Â± 2.1; P = 0.0000). The frequency of adverse effects, i.e. mild gastrointestinal manifestations and headache which did not require discontinuation of the treatment, in the EG during the study period was 15.6%.

CONCLUSION: Our findings indicated positive effects of carbocysteine regarding the frequency and duration of exacerbations, as well as its good tolerability in the patients with bronchiectasis.